` CUV (Clinuvel Pharmaceuticals Ltd) vs S&P/ASX 300 Comparison - Alpha Spread

CUV
vs
S&P/ASX 300

Over the past 12 months, CUV has underperformed S&P/ASX 300, delivering a return of -31% compared to the S&P/ASX 300's 7% growth.

Stocks Performance
CUV vs S&P/ASX 300

Loading

Performance Gap
CUV vs S&P/ASX 300

Loading
CUV
S&P/ASX 300
Difference

Performance By Year
CUV vs S&P/ASX 300

Loading
CUV
S&P/ASX 300
Add Stock

Competitors Performance
Clinuvel Pharmaceuticals Ltd vs Peers

S&P/ASX 300
CUV
ABBV
AMGN
GILD
VRTX
Add Stock

Clinuvel Pharmaceuticals Ltd
Glance View

Market Cap
528.6m AUD
Industry
Biotechnology

Clinuvel Pharmaceuticals Ltd. operates as a biopharmaceutical company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2001-02-13. The firm is focused on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders, as well as healthcare solutions for the general population. The Company’s principal activity consists of commercializing and distribution in Europe and the United States of its drug candidate SCENESSE for the treatment of a rare, genetic metabolic disorder erythropoietic protoporphyria (EPP). The company is also focused on developing and commercializing SCENESSE as a combination with narrowband ultraviolet B (NB-UVB) phototherapy and topical pharmaceutical formulations of melanocortin analogues for the treatment of the skin depigmentation disorder vitiligo. Its research and development of PRENUMBRA, a new liquid formulation of afamelanotide for the treatment of acute disorders and vascular anomalies.

CUV Intrinsic Value
14.33 AUD
Undervaluation 26%
Intrinsic Value
Price
Back to Top